Literature DB >> 18755212

Effects of the monoamine uptake inhibitors RTI-112 and RTI-113 on cocaine- and food-maintained responding in rhesus monkeys.

S S Negus1, N K Mello, H L Kimmel, L L Howell, F I Carroll.   

Abstract

Cocaine blocks uptake of the monoamines dopamine, serotonin and norepinephrine, and monoamine uptake inhibitors constitute one class of drugs under consideration as candidate "agonist" medications for the treatment of cocaine abuse and dependence. The pharmacological selectivity of monoamine uptake inhibitors to block uptake of dopamine, serotonin and norepinephrine is one factor that may influence the efficacy and/or safety of these compounds as drug abuse treatment medications. To address this issue, the present study compared the effects of 7-day treatment with a non-selective monoamine uptake inhibitor (RTI-112) and a dopamine-selective uptake inhibitor (RTI-113) on cocaine- and food-maintained responding in rhesus monkeys. Monkeys (N=3) were trained to respond for cocaine injections (0.01 mg/kg/inj) and food pellets under a second-order schedule [FR2(VR16:S)] during alternating daily components of cocaine and food availability. Both RTI-112 (0.0032-0.01 mg/kg/hr) and RTI-113 (0.01-0.056 mg/kg/h) produced dose-dependent, sustained and nearly complete elimination of cocaine self-administration. However, for both drugs, the potency to reduce cocaine self-administration was similar to the potency to reduce food-maintained responding. These findings do not support the hypothesis that pharmacological selectivity to block dopamine uptake is associated with behavioral selectivity to decrease cocaine- vs. food-maintained responding in rhesus monkeys.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18755212      PMCID: PMC2645592          DOI: 10.1016/j.pbb.2008.08.002

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  31 in total

Review 1.  The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates.

Authors:  L L Howell; K M Wilcox
Journal:  J Pharmacol Exp Ther       Date:  2001-07       Impact factor: 4.030

Review 2.  Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.

Authors:  John Grabowski; James Shearer; John Merrill; S Stevens Negus
Journal:  Addict Behav       Date:  2004-09       Impact factor: 3.913

3.  Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys.

Authors:  Nancy K Mello; S Stevens Negus; Kenner C Rice; Jack H Mendelson
Journal:  Pharmacol Biochem Behav       Date:  2006-12-19       Impact factor: 3.533

4.  Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys.

Authors:  S S Negus; N K Mello; X Lamas; J H Mendelson
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

5.  Sustained decrease in cocaine-maintained responding in rhesus monkeys with 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-hydroxy-3-phenylpropyl) piperazinyl decanoate, a long-acting ester derivative of GBR 12909.

Authors:  J R Glowa; W E Fantegrossi; D B Lewis; D Matecka; K C Rice; R B Rothman
Journal:  J Med Chem       Date:  1996-11-22       Impact factor: 7.446

6.  Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys.

Authors:  S Stevens Negus; Nancy K Mello
Journal:  Drug Alcohol Depend       Date:  2003-05-01       Impact factor: 4.492

7.  Effects of the mixed-action kappa/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys.

Authors:  Glenn W Stevenson; Mark P Wentland; Jean M Bidlack; Nancy K Mello; S Stevens Negus
Journal:  Eur J Pharmacol       Date:  2004-12-15       Impact factor: 4.432

8.  Effects of continuous infusions of SCH 23390 on cocaine- or food-maintained behavior in rhesus monkeys.

Authors:  M.S. Kleven; W.L. Woolverton
Journal:  Behav Pharmacol       Date:  1990       Impact factor: 2.293

9.  RTI-113 administration reduces cocaine self-administration at high occupancy of dopamine transporter.

Authors:  S I Dworkin; P Lambert; G M Sizemore; F I Carroll; M J Kuhar
Journal:  Synapse       Date:  1998-09       Impact factor: 2.562

Review 10.  A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909.

Authors:  R B Rothman; J R Glowa
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

View more
  10 in total

1.  Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142.

Authors:  Megan J Moerke; Subramaniam Ananthan; Matthew L Banks; Jose M Eltit; Kelen C Freitas; Amy R Johnson; Surendra K Saini; Tyler W E Steele; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2018-08-27       Impact factor: 4.030

2.  CTDP-32476: A Promising Agonist Therapy for Treatment of Cocaine Addiction.

Authors:  Zheng-Xiong Xi; Rui Song; Xia Li; Guan-Yi Lu; Xiao-Qing Peng; Yi He; Guo-Hua Bi; Siyuan Peter Sheng; Hong-Ju Yang; Haiying Zhang; Jin Li; Mark Froimowitz; Eliot L Gardner
Journal:  Neuropsychopharmacology       Date:  2016-08-18       Impact factor: 7.853

Review 3.  Monoamine transporter inhibitors and substrates as treatments for stimulant abuse.

Authors:  Leonard L Howell; S Stevens Negus
Journal:  Adv Pharmacol       Date:  2014

4.  The selective dopamine uptake inhibitor, D-84, suppresses cocaine self-administration, but does not occasion cocaine-like levels of generalization.

Authors:  Angela M Batman; Aloke K Dutta; Maarten E A Reith; Patrick M Beardsley
Journal:  Eur J Pharmacol       Date:  2010-09-16       Impact factor: 4.432

5.  Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys.

Authors:  Jennifer L Newman; S Stevens Negus; Anthony Lozama; Thomas E Prisinzano; Nancy K Mello
Journal:  Exp Clin Psychopharmacol       Date:  2010-10       Impact factor: 3.157

6.  A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse.

Authors:  Remy L Brim; Mark R Nance; Daniel W Youngstrom; Diwahar Narasimhan; Chang-Guo Zhan; John J G Tesmer; Roger K Sunahara; James H Woods
Journal:  Mol Pharmacol       Date:  2010-01-19       Impact factor: 4.436

7.  A dopamine transport inhibitor with markedly low abuse liability suppresses cocaine self-administration in the rat.

Authors:  Antonio Ferragud; Clara Velázquez-Sánchez; Vicente Hernández-Rabaza; Amparo Nácher; Virginia Merino; Miguel Cardá; Juan Murga; Juan J Canales
Journal:  Psychopharmacology (Berl)       Date:  2009-09-16       Impact factor: 4.530

8.  Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine.

Authors:  S S Negus; M H Baumann; R B Rothman; N K Mello; B E Blough
Journal:  J Pharmacol Exp Ther       Date:  2009-01-16       Impact factor: 4.030

9.  Effects of chronic methylphenidate on cocaine self-administration under a progressive-ratio schedule of reinforcement in rhesus monkeys.

Authors:  Paul W Czoty; Susan E Martelle; Robert W Gould; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2013-04-11       Impact factor: 4.030

10.  PEGylation but Not Fc-Fusion Improves in Vivo Residence Time of a Thermostable Mutant of Bacterial Cocaine Esterase.

Authors:  Haifeng Huang; Lei Fang; Liu Xue; Ting Zhang; Kyungbo Kim; Shurong Hou; Fang Zheng; Chang-Guo Zhan
Journal:  Bioconjug Chem       Date:  2019-11-25       Impact factor: 4.774

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.